Published July 14, 2022 | Version v1
Journal article Open

Cancer vaccine treatment for Melanoma

Authors/Creators

  • 1. Mahidol University International Demonstration School, Salaya, Phutthamonthon, Nakhon Pathom, Thailand 73170

Description

Abstract: Generally, cancer is a serious problem no matter what type of cancer, even though we have many types of medication, including vaccination. Most vaccines are created to prevent or boost immunity. However, the vaccine that this literature review mentioned was made to treat cancer. As the medical professionals wanted to treat the cancer patients precisely, a cancer vaccine was developed, not for prevention but as a cure by tricking the immune system. The vaccines have been developed using four melanoma antigens groups: overexpressed antigens, cancer-testis antigens, mutant oncogenes, and patient-specific mutated neoantigens. In addition, two technologies, Tumor antigens and Stimulation of anti-tumour immunity, have advanced based on the mechanism of cancer vaccines. Most importantly, the critical potential of cancer vaccine treatment for Melanoma has some clinical studies about the vaccinations that have been advanced and existed in much research, plus, it has been tested with humans. The history of melanoma skin cancer immunizations is extensive. It can stimulate immunological responses. An efficient vaccination platform is examined in this dynamic sector. This includes immunizations based on neoantigens and skin cancer virus inclusions.

Keywords: Cancer vaccines, Melanoma antigens, Melanoma, Tumor antigens.

Title: Cancer vaccine treatment for Melanoma

Author: Supavee Piyapanpong

International Journal of Healthcare Sciences

ISSN 2348-5728 (Online)

Vol. 10, Issue 1, April 2022 - September 2022

Page No: 144-152

Research Publish Journals

Website: www.researchpublish.com

Published Date: 14-July-2022

DOI: https://doi.org/10.5281/zenodo.6832997

Paper Download Link (Source)

https://www.researchpublish.com/papers/cancer-vaccine-treatment-for-melanoma

Notes

International Journal of Healthcare Sciences, ISSN 2348-5728 (Online), Research Publish Journals, Website: www.researchpublish.com

Files

Cancer vaccine treatment-14072022-4.pdf

Files (718.2 kB)

Name Size Download all
md5:f58718933c2fd863060b5bb4fe026a7c
718.2 kB Preview Download

Additional details

Related works

Is published in
Journal article: 2348-5728 (ISSN)
Journal article: https://www.researchpublish.com/papers/cancer-vaccine-treatment-for-melanoma (URL)

References

  • [1] W. S. Bowen, A. K. Svrivastava, L. Batra, H. Barsoumian, and H. Shirwan, "Current challenges for cancer vaccine adjuvant development," Expert review of vaccines, vol. 17, no. 3, pp. 207-215, 2018.
  • [2] M. Yazdani, M. R. Jaafari, J. Verdi, B. Alani, M. Noureddini, and A. Badiee, "Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems," Immunotherapy, vol. 12, no. 5, pp. 333-349, 2020.
  • [3] C. O. Franck, L. Fanslau, A. Bistrovic Popov, P. Tyagi, and L. Fruk, "Biopolymer‐based carriers for DNA vaccine design," Angewandte Chemie International Edition, vol. 60, no. 24, pp. 13225-13243, 2021.
  • [4] Z. Liu et al., "Gastrodin, a traditional Chinese medicine monomer compound, can be used as adjuvant to enhance the immunogenicity of melanoma vaccines," International Immunopharmacology, vol. 74, p. 105699, 2019.
  • [5] I. Falcone et al., "Tumor microenvironment: Implications in melanoma resistance to targeted therapy and immunotherapy," Cancers, vol. 12, no. 10, p. 2870, 2020.
  • [6] M. Antohe et al., "Tumor infiltrating lymphocytes: The regulator of melanoma evolution," Oncology letters, vol. 17, no. 5, pp. 4155-4161, 2019.
  • [7] M. W. Rohaan, J. H. van den Berg, P. Kvistborg, and J. B. A. G. Haanen, "Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option," Journal for immunotherapy of cancer, vol. 6, no. 1, pp. 1-16, 2018.
  • [8] L. H. Butterfield et al., "Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma," Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 1-15, 2019.
  • [9] L. Liu, M. J. Wannemuehler, and B. Narasimhan, "Biomaterial nanocarrier-driven mechanisms to modulate anti-tumor immunity," Current Opinion in Biomedical Engineering, vol. 20, p. 100322, 2021.
  • [10] I. Date et al., "Interferon-α-induced dendritic cells generated with human platelet lysate exhibit elevated antigen presenting ability to cytotoxic T lymphocytes," Vaccines, vol. 9, no. 1, p. 10, 2020.
  • [11] R. Mortarini et al., "Autologous Dendritic Cells Derived from CD34+ Progenitors and from Monocytes Are Not Functionally Equivalent Antigen-presenting Cells in the Induction of Melan-A/Mart-l27_35-specific CTLs from Peripheral Blood Lymphocytes of Melanoma Patients with Low Frequency of CTL Precursors1."
  • [12] B. K. Patel, C. Wang, B. Lorens, A. D. Levine, N. F. Steinmetz, and S. Shukla, "Cowpea Mosaic Virus (CPMV)-Based Cancer Testis Antigen NY-ESO-1 Vaccine Elicits an Antigen-Specific Cytotoxic T Cell Response," (in eng), ACS Appl Bio Mater, vol. 3, no. 7, pp. 4179-4187, Jul 20 2020, doi: 10.1021/acsabm.0c00259.
  • [13] A. Mougel, M. Terme, and C. Tanchot, "Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade," Frontiers in immunology, vol. 10, p. 467, 2019.
  • [14] Y.-C. Chuang, J.-C. Tseng, L.-R. Huang, C.-M. Huang, C.-Y. F. Huang, and T.-H. Chuang, "Adjuvant effect of toll-like receptor 9 activation on cancer immunotherapy using checkpoint blockade," Frontiers in Immunology, vol. 11, p. 1075, 2020.
  • [15] R. Luthra, S. Datta, and A. Roy, "Role of Different Peptides for Cancer Immunotherapy," International Journal of Peptide Research and Therapeutics, vol. 27, no. 4, pp. 2777-2793, 2021.

Subjects

Paper Download Link (Source)
https://www.researchpublish.com/papers/cancer-vaccine-treatment-for-melanoma